Page 19 - Cipla

Cipla hits 52-wk high on launch of generic remdesivir for Covid-19 patients

Remdesivir is the only USFDA approved emergency use authorization treatment in severe (hospitalised) Covid-19 patients.

Hetero to launch remdesivir at Rs 5,000-6,000/dose, Cipla to follow suit

Industry sources estimate that at least 10,000 patients need the drug urgently in the areas with high case load

Covid-19 crisis: Cipla launches generic remdesivir under brand name Cipremi

The USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of Covid-19 patients

Covid-19 crisis: Made-in-India remdesivir may come by end of June

Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.

Roche Pharma India expands partnership with Cipla for oncology medicines

The two companies had previously entered into a similar agreement in February 2018 for promotion and distribution of tocilizumab (Actemra) and other products

Covid-19 crisis: Gilead working on combo of remdesivir, other drugs

Patient recruitment for the tocilizumab combination therapy study will begin this month.

US respiratory pipeline breathes in fresh optimism for Cipla; stock up 5%

Improving growth in North America will complement strong domestic sales

Cipla working on multiple therapies to fight spread of coronavirus

Besides, the company is reworking its domestic market sales strategy, and scrutinising its capital and operating expenditure plans

Cipla's profit before tax dips 35% to Rs 327.9 cr; India business grows 12%

The net profit came down 33 per cent to Rs 246 crore, lower than Street expectations. Emkay Global had expected a 3 per cent dip in profit for the quarter.

MARKET WRAP: Indices end flat, Sensex slips 25 pts; financials, autos fall

All that happened in the markets today

Market Ahead, May 15: All You Need To Know Before The Opening Bell

Today, a total of 12 companies including Cipla, Aaarti Drugs, and M&M Finance are scheduled to announce their results

Indian drug makers gear up to make Gilead's remdesivir for Covid-19 therapy

Domestic players will be free to price it; Dutch firm Mylan also to make the drug in India; no royalty for Gilead as yet

Gilead enters licensing pact with 5 drug firms in India, Pak for remdesivir

According to the agreement the companies Cipla, Hetero Labs, Jubilant Life Sciences, Mylan, and Pakistan based Ferozsons Labs, to manufacture and sell remdesivir in 127 countries

Jubilant Life, Cipla rally up to 6% on inking pact with Gilead Sciences

According to the statements issued by Jubilant Life and Cipla, both the firms will have the right to register, manufacture and sell Gilead's Remdesivir drug in 127 countries including India

Centre keen on testing Gilead's remdesivir to combat coronavirus

The USFDA has recently given an emergency approval to the drug for use on coronavirus patients

Nifty to face stiff resistance at 9,500 levels: Gaurav Garg of CapitalVia

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

India gears up for patient trials on 20 different drugs for Covid-19

Local pharma units have already started work on developing patented drugs, some have already approached regulator for approvals

Cipla Health partners Swiggy, Zomato, Dunzo to deliver wellness products

Cipla Health will cater to 4 lakh people and cover 250 stores in 45 cities across the country

Coronavirus outbreak: Quick USFDA approvals for asthma drug makers

Cipla gets nod for drug from USFDA earlier than expected; Lupin in fray

Cipla surges 15% on USFDA nod for first generic Proventil HFA inhaler

Proventil HFA (albuterol sulfate) metered-dose inhaler is used for the treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms.